ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued twelve-month target prices for ANI Pharmaceuticals' shares. Their ANIP share price targets range from $77.00 to $83.00. On average, they anticipate the company's stock price to reach $80.00 in the next year. This suggests a possible upside of 23.0% from the stock's current price.
View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts.

ANI Pharmaceuticals' stock was trading at $55.14 on January 1st, 2024. Since then, ANIP stock has increased by 17.9% and is now trading at $65.02.
View the best growth stocks for 2024 here.

ANI Pharmaceuticals saw a decline in short interest in March. As of March 31st, there was short interest totaling 197,000 shares, a decline of 24.7% from the March 15th total of 261,600 shares. Based on an average trading volume of 137,600 shares, the days-to-cover ratio is presently 1.4 days.
View ANI Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ANIP earnings forecast.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its quarterly earnings results on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The specialty pharmaceutical company earned $131.65 million during the quarter, compared to analysts' expectations of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a trailing twelve-month return on equity of 18.06%.

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

ANI Pharmaceuticals issued an update on its FY24 earnings guidance on Tuesday, March, 12th. The company provided earnings per share guidance of $4.26-4.67 for the period, compared to the consensus earnings per share estimate of $4.46. The company issued revenue guidance of $520-542 million, compared to the consensus revenue estimate of $535.21 million.

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

ANI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.12%) and BTC Capital Management Inc. (0.04%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Stephen P Carey and Thomas Haughey.
View institutional ownership trends.

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.